Thyroxine-binding globulin (TBG) is aglobulinprotein encoded by theSERPINA7gene in humans. TBG bindsthyroid hormones incirculation. It is one of threetransport proteins (along withtransthyretin andserum albumin) responsible forcarrying the thyroid hormonesthyroxine (T4) andtriiodothyronine (T3) in the bloodstream. Of these three proteins, TBG has the highest affinity for T4 and T3 but is present in the lowestconcentration relative to transthyretin and albumin, which also bind T3 and T4 in circulation. Despite its low concentration, TBG carries the majority of T4 in theblood plasma. Due to the very low concentration of T4 and T3 in the blood, TBG is rarely more than 25% saturated with itsligand. Unlike transthyretin and albumin, TBG has a single binding site for T4/T3. TBG issynthesized primarily in theliver as a 54-kDa protein. In terms ofgenomics, TBG is aserpin; however, it has no inhibitory function like many other members of this class of proteins.
Thyroxine-binding globulin tests are sometimes used to find the cause of raised or lowered levels of thyroid hormone. This is done by measuring resin binding to labeled thyroid hormone, which happens only when the labeled thyroid hormone is free.
The patient's serum is mixed with the labeled thyroid hormone; next, the resin is added to the whole mixture to measure the amount of free labeled thyroid hormone. So, for instance, if the patient is truly hypothyroid, and TBG levels are normal, then there are many sites open for binding on the TBG, since the total thyroid hormone level is low. Therefore, when the labeled hormone is added, it will bind mostly to the TBG, leaving little of it left for binding to the resin. In contrast, however, if the patient is truly hyperthyroid, and TBG levels are normal, the patient's endogenous hormone will saturate the TBG binding sites more, leaving less room for the labeled hormone, which allows greater binding to the resin.
In patients who are truly hypo- or hyperthyroid, TBG testing is not very useful. However, if total thyroid hormone levels point to hypothyroidism or hyperthyroidism in the absence of accompanying symptoms, the utility of TBG testing becomes more evident, since TBG production can be modified by other factors such as estrogen levels, corticosteroid levels, or liver failure. If, for example, the TBG level is high, which can occur when estrogen levels are high, the TBG will bind more thyroid hormone, decreasing the free hormone available in the blood, which leads to stimulation ofTSH, and the production of more thyroid hormone. In this case, the total thyroid hormone level will be high. And so, when labeled hormone is added, since TBG is so high, once equilibrium between the binding of endogenous thyroid hormone and the labeled hormone is achieved, less free labeled hormone will be available for uptake into the resin. On the converse, in the presence of corticosteroids, which lower TBG levels, the total thyroid hormone (bound and free) in the blood will be low. Thus, when the labeled hormone is added, since so little TBG is available in the blood, after equilibrium is achieved, only a small portion of it will bind, leaving plenty available for uptake by the resin.
Cheng SY (1978). "Partial amino acid sequence of human thyroxine-binding globulin. Further evidence for a single polypeptide chain".Biochem. Biophys. Res. Commun.79 (4):1212–8.doi:10.1016/0006-291X(77)91135-4.PMID414747.
Bertenshaw R, Sarne D, Tornari J, et al. (1992). "Sequencing of the variant thyroxine-binding globulin (TBG)-San Diego reveals two nucleotide substitutions".Biochim. Biophys. Acta.1139 (4):307–10.doi:10.1016/0925-4439(92)90105-v.PMID1515456.
Imamura S, Mori Y, Murata Y, et al. (1991). "Molecular cloning and primary structure of rat thyroxine-binding globulin".Biochemistry.30 (22):5406–11.doi:10.1021/bi00236a012.PMID1903654.
Janssen OE, Takeda K, Refetoff S (1991). "Sequence of the variant thyroxine-binding globulin (TBG) in a Montreal family with partial TBG deficiency".Hum. Genet.87 (2):119–22.doi:10.1007/BF00204164.PMID1906047.S2CID9241072.
Yamamori I, Mori Y, Seo H, et al. (1991). "Nucleotide deletion resulting in frameshift as a possible cause of complete thyroxine-binding globulin deficiency in six Japanese families".J. Clin. Endocrinol. Metab.73 (2):262–7.doi:10.1210/jcem-73-2-262.PMID1906892.
Li P, Janssen OE, Takeda K, et al. (1991). "Complete thyroxine-binding globulin (TBG) deficiency caused by a single nucleotide deletion in the TBG gene".Metab. Clin. Exp.40 (11):1231–4.doi:10.1016/0026-0495(91)90221-h.PMID1943753.
Waltz MR, Pullman TN, Takeda K, et al. (1990). "Molecular basis for the properties of the thyroxine-binding globulin-slow variant in American blacks".J. Endocrinol. Invest.13 (4):343–9.doi:10.1007/bf03349576.PMID2115061.S2CID22555365.
Mori Y, Takeda K, Charbonneau M, Refetoff S (1990). "Replacement of Leu227 by Pro in thyroxine-binding globulin (TBG) is associated with complete TBG deficiency in three of eight families with this inherited defect".J. Clin. Endocrinol. Metab.70 (3):804–9.doi:10.1210/jcem-70-3-804.PMID2155256.
Mori Y, Miura Y, Oiso Y, et al. (1995). "Precise localization of the human thyroxine-binding globulin gene to chromosome Xq22.2 by fluorescence in situ hybridization".Hum. Genet.96 (4):481–2.doi:10.1007/BF00191811.PMID7557975.S2CID33967655.
Akbari MT, Kapadi A, Farmer MJ, et al. (1994). "The structure of the human thyroxine binding globulin (TBG) gene".Biochim. Biophys. Acta.1216 (3):446–54.doi:10.1016/0167-4781(93)90013-4.PMID8268226.
Mori Y, Miura Y, Takeuchi H, et al. (1996). "Gene amplification as a cause of inherited thyroxine-binding globulin excess in two Japanese families".J. Clin. Endocrinol. Metab.80 (12):3758–62.doi:10.1210/jcem.80.12.8530630.PMID8530630.
Carvalho GA, Weiss RE, Vladutiu AO, Refetoff S (1998). "Complete deficiency of thyroxine-binding globulin (TBG-CD Buffalo) caused by a new nonsense mutation in the thyroxine-binding globulin gene".Thyroid.8 (2):161–5.doi:10.1089/thy.1998.8.161.PMID9510125.
